Current Report Filing (8-k)
July 05 2018 - 3:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
July 3,
2018
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
|
Nevada
|
000-52138
|
20-2000871
|
|
(State or other jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
|
incorporation)
|
|
Identification No.)
|
|
156 Valleyview Road, Kelowna, BC Canada
|
V1X 3M4
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code
(250) 765-6424
N/A
(Former name or former address, if
changed since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e -4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2
of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
[ ]
Item 5.07
Submission of Matters to a Vote of Security Holders
On June 13, 2018 at 11:00 a.m. (Pacific Time), Lexaria
Bioscience Corp. ("Lexaria" or the "Company") held its annual and special
meeting of shareholders for the following purposes and all proposals were
approved by the shareholders with the following voting results:
- 2 -
|
FOR
|
Percent
|
Against
|
Abstain or
Withheld
|
Percent
|
|
To Elect Directors:
|
|
|
|
|
|
|
- Chris Bunka
|
15,759,626
|
99.42%
|
N/A
|
91,821
|
0.58%
|
|
- John Docherty
|
15,759,654
|
99.42%
|
N/A
|
91,793
|
0.58%
|
|
- Nicholas Baxter
|
15,762,247
|
99.44%
|
N/A
|
89,200
|
0.56%
|
|
- Ted McKechnie
|
15,761,335
|
99.43%
|
N/A
|
90,112
|
0.57%
|
|
Appoint Auditors
|
39,226,013
|
99.79%
|
N/A
|
83,110
|
0.21%
|
|
Plan of Conversion to change the corporate
jurisdiction from the State of Nevada to the Province of British Columbia
|
15,324,943
|
96.68%
|
526,504
|
0
|
3.32%
|
|
Other Business (None)
|
15,756,580
|
99.40%
|
94,867
|
0
|
0.60%
|
All of the proposals are described in detail in the Company's
proxy statement/prospectus filed with the Securities and Exchange Commission on
April 9, 2018:
Item 7.01
Regulation FD Disclosure
A copy of the news release announcing the results of the 2018
Annual General and Special Meeting and update on Corporate restructuring is
filed as exhibit 99.1 to this current report and is hereby incorporated by
reference.
Item 9.01
Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
|
/s/ Chris
Bunka
|
|
|
Chris Bunka
|
|
|
CEO, Principal Executive Officer
|
|
|
|
|
|
Date: July 5, 2018
|
|